Dapaglifozin

DRUG2 trials

Sponsors

MedImmune LLC, University Hospital, Strasbourg, France

Conditions

Septic ShockType 2 Diabetes Mellitus

Phase 2

Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes

CompletedNCT03444584

MedImmune LLCType 2 Diabetes Mellitus

Start: 2018-05-08End: 2018-12-06Updated: 2020-01-13

Phase 3

Assessing the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic Shock Patients With Microcirculatory Dysfunction

Not yet recruitingNCT07488689

University Hospital, Strasbourg, FranceSeptic Shock

Start: 2026-07-01End: 2030-07-01Target: 568Updated: 2026-03-27